ERBB2 and breast cancer: Although the NSABP B-47 (NCT01275677) study evaluated the efficacy of adjuvant chemotherapy with or without the monoclonal antibody trastuzumab in the treatment of subjects with HER2-low BC, the results were not satisfactory (Fehrenbacher et al., 2020).